These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 8101146

  • 1. Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
    Ur E, Bomanji J, Mather SJ, Britton KE, Wass JA, Grossman AB, Besser GM.
    Clin Endocrinol (Oxf); 1993 May; 38(5):501-6. PubMed ID: 8101146
    [Abstract] [Full Text] [Related]

  • 2. In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCT.
    Virgolini I, Angelberger P, Li S, Yang Q, Kurtaran A, Raderer M, Neuhold N, Kaserer K, Leimer M, Peck-Radosavljevic M, Scheithauer W, Niederle B, Eichler HG, Valent P.
    Eur J Nucl Med; 1996 Oct; 23(10):1388-99. PubMed ID: 8781146
    [Abstract] [Full Text] [Related]

  • 3. Imaging neuroendocrine tumours with radiolabelled somatostatin analogues and X-ray computed tomography: a comparative study.
    King CM, Reznek RH, Bomanji J, Ur E, Britton KE, Grossman AB, Besser GM.
    Clin Radiol; 1993 Dec; 48(6):386-91. PubMed ID: 8293643
    [Abstract] [Full Text] [Related]

  • 4. Somatostatin receptor imaging in intracranial tumours.
    Schmidt M, Scheidhauer K, Luyken C, Voth E, Hildebrandt G, Klug N, Schicha H.
    Eur J Nucl Med; 1998 Jul; 25(7):675-86. PubMed ID: 9662588
    [Abstract] [Full Text] [Related]

  • 5. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.
    Breeman WA, Hofland LJ, van der Pluijm M, van Koetsveld PM, de Jong M, Setyono-Han B, Bakker WH, Kwekkeboom DJ, Visser TJ, Lamberts SW.
    Eur J Nucl Med; 1994 Apr; 21(4):328-35. PubMed ID: 7911760
    [Abstract] [Full Text] [Related]

  • 6. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
    Bangard M, Béhé M, Guhlke S, Otte R, Bender H, Maecke HR, Biersack HJ.
    Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
    [Abstract] [Full Text] [Related]

  • 7. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.
    Krenning EP, Bakker WH, Kooij PP, Breeman WA, Oei HY, de Jong M, Reubi JC, Visser TJ, Bruns C, Kwekkeboom DJ.
    J Nucl Med; 1992 May; 33(5):652-8. PubMed ID: 1349039
    [Abstract] [Full Text] [Related]

  • 8. Somatostatin receptor scintigraphy using [111In-DTPA0]RC-160 in humans: a comparison with [111In-DTPA0]octreotide.
    Breeman WA, van Hagen PM, Kwekkeboom DJ, Visser TJ, Krenning EP.
    Eur J Nucl Med; 1998 Feb; 25(2):182-6. PubMed ID: 9473268
    [Abstract] [Full Text] [Related]

  • 9. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours.
    Schillaci O, Corleto VD, Annibale B, Scopinaro F, Delle Fave G.
    Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S186-9. PubMed ID: 10604127
    [Abstract] [Full Text] [Related]

  • 10. In vitro and in vivo detection of functional somatostatin receptors in canine insulinomas.
    Robben JH, Visser-Wisselaar HA, Rutteman GR, van Rijk PP, van Dongen AJ, Voorhout G, van den Ingh TS, Hofland LJ, Lamberts SW.
    J Nucl Med; 1997 Jul; 38(7):1036-42. PubMed ID: 9225787
    [Abstract] [Full Text] [Related]

  • 11. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging.
    Shi W, Johnston CF, Buchanan KD, Ferguson WR, Laird JD, Crothers JG, McIlrath EM.
    QJM; 1998 Apr; 91(4):295-301. PubMed ID: 9666953
    [Abstract] [Full Text] [Related]

  • 12. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.
    Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC.
    Eur J Nucl Med; 1993 Aug; 20(8):716-31. PubMed ID: 8404961
    [Abstract] [Full Text] [Related]

  • 13. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
    Barone R, Walrand S, Konijnenberg M, Valkema R, Kvols LK, Krenning EP, Pauwels S, Jamar F.
    Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
    [Abstract] [Full Text] [Related]

  • 14. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.
    Capello A, Krenning E, Bernard B, Reubi JC, Breeman W, de Jong M.
    Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1288-95. PubMed ID: 16021448
    [Abstract] [Full Text] [Related]

  • 15. Pituitary imaging using a labelled somatostatin analogue in acromegaly.
    Ur E, Mather SJ, Bomanji J, Ellison D, Britton KE, Grossman AB, Wass JA, Besser GM.
    Clin Endocrinol (Oxf); 1992 Feb; 36(2):147-50. PubMed ID: 1348978
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.
    Kowalski J, Henze M, Schuhmacher J, Mäcke HR, Hofmann M, Haberkorn U.
    Mol Imaging Biol; 2003 Feb; 5(1):42-8. PubMed ID: 14499161
    [Abstract] [Full Text] [Related]

  • 17. Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide.
    Westlin JE, Janson ET, Arnberg H, Ahlström H, Oberg K, Nilsson S.
    Acta Oncol; 1993 Feb; 32(7-8):783-6. PubMed ID: 8305227
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment.
    Shi W, Buchanan KD, Johnston CF, Larkin C, Ong YL, Ferguson R, Laird J.
    Clin Endocrinol (Oxf); 1998 Mar; 48(3):303-9. PubMed ID: 9578820
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.